AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality, the first appraisal will be conducted in private. The final appraisal recommendation will be announced in public.

5. Appraisal 1 – Limited submission (PAS)
   Tocilizumab (RoActemra®) in combination with methotrexate (MTX) for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

The meeting will now open to the public (approx 11.15 am).

6. Chairman’s report (verbal update)

7. AWMG Patient and Public Engagement Strategy

8. AWMG Process for appraising medicines in light of negative NICE recommendation

9. AWMG Process for considering the adoption / implementation of NICE Highly Specialised Technologies (HST) advice

10. Appraisal 2 – Full submission
    Bromfenac (Yellox®) for treatment of postoperative ocular inflammation following cataract extraction in adults

Appendices
11. **Appraisal 3 – Limited submission**
   Tenofovir disoproxil fumarate (Viread®) for the treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus  
    
12. **Appraisal 4 – Limited submission**
   Indacaterol/glycopyrronium (Ultibro® Breezhaler®) indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease  
    
13. **National Prescribing Indicators Quarterly report – September 2013**  
    
14. **Antidotes in Wales**  
    
**Date of next meeting:**
**Wednesday 2\textsuperscript{nd} April 2014 in Abergavenny**